Factor XI and XII as antithrombotic targets

Current Opinion in Hematology

Volumn 18, Issue 5, 2011, Pages 349-355

  Müller, Felicitas ^a,b,c   Gailani, David ^d   Renné, Thomas ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

factor XI; factor XII; hemostasis; intrinsic pathway of coagulation; polyphosphate; thrombosis

Indexed keywords

3 CARBOXAMIDE COUMARIN INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; BMS 262084; CLAVATADINE A; CLAVATADINE B; COMPOUND 32; CONTACT PHASE INHIBITOR; DABIGATRAN ETEXILATE; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FONDAPARINUX; HEPARIN; HUMAN ALBUMIN; INFESTIN 4; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14E11; MONOCLONAL ANTIBODY O1A6; NEUTRALIZING ANTIBODY; PROTEIN INHIBITOR; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; DRUG TARGETING; GRAFT OCCLUSION; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LUNG EMBOLISM; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XI; FACTOR XI DEFICIENCY; FACTOR XII; FACTOR XII DEFICIENCY; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 80051794851     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283497e61     Document Type: Review

References (71)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-918. (Pubitemid 351301746)
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-949.
3. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
4. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498-499.
5. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009;108:1447-1452.
6. Colman RW. Contact activation (kallikrein-kinin) pathway: multiple physiologic and pathophysiologic activities. In Colman RW, Mader VJ, Clowes AW, et al. editors. Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 107-130.
7. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-1156. The study identifies polyphosphate (an inorganic polymer) as the activator of the FXII-driven intrinsic pathway of coagulation on procoagulant platelets. Polyphosphates initiate thrombosis in animal models and patients and provide procoagulant activity to propagate arterial thrombi in a FXII-dependent manner.
8. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007;27:2507-2513. (Pubitemid 350158899)
9. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991;253:909-912. (Pubitemid 21917236)
10. Gailani D, Sun MF, Cheng Q, et al. Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7. Blood 2010;116:1185-1186; author reply 1186-1187.
11. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955;34:602-613.
12. Rosen ED, Chan JC, Idusogie E, et al. Mice lacking factorVII develop normally but suffer fatal perinatal bleeding. Nature 1997;390:290-294. (Pubitemid 27513311)
13. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996;93:6258-6263.
14. Saunders RE, Shiltagh N, Gomez K, et al. Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thromb Haemost 2009;102:287-301.
15. Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009;114:452-458.
16. Morrissey JH. Tissue factor: in at the start...and the finish? J Thromb Haemost 2003;1:878-880.
17. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factorXI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-3042.
18. Gailani D, Lasky NM, Broze GJ Jr. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997;8:134-144. (Pubitemid 27211727)
19. Pauer HU, Renne T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII gene: a model for contact phase activation in vivo. Thromb Haemost 2004;92:503-508. (Pubitemid 39248007)
20. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-281. (Pubitemid 41043823)
21. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002;87:774-776. (Pubitemid 34302972)
22. Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005;3:695-702. (Pubitemid 41647883)
23. Wang X, Smith PL, Hsu MY, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006;4:1982-1988. (Pubitemid 44226778)
24. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-518.
25. Pham M, Kleinschnitz C, Helluy X, et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. Neuroimage 2010;49:2907-2914.
26. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010;116:3981-3989.
27. Renne T, Gailani D. Role of factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 2007;5:733-741. (Pubitemid 47050183)
28. Doolittle RF. Coagulation in vertebrates with a focus on evolution and inflammation. J Innate Immun 2011;3:9-16.
29. Maas C, Oschatz C, Renne T. Activators of the contact system 2.0. Semin Thromb Hemost (in press).
30. Walsh PN. The role of platelets in the contact phase of blood coagulation. Br J Haematol 1972;22:237-254.
31. Muller F, Renne T. Platelet polyphosphates: the nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 2011;71:82-86.
32. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-3218.
33. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011;34:258-268.
34. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005;175:3377-3385. (Pubitemid 41170560)
35. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000;275:33688-33696.
36. Ratnoff OD. The demise of John Hageman. N Engl J Med 1968;279:760-761.
37. Girolami A, Randi ML, Gavasso S, et al. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 2004;17:139-143. (Pubitemid 39157964)
38. Bach J, Endler G, Winkelmann BR, et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008;6:291-296.
39. Halbmayer WM, Mannhalter C, Feichtinger C, et al. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992;68:285-290.
40. Girolami A, Morello M, Girolami B, et al. Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 2005;11:49-53. (Pubitemid 40194197)
41. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 1994;87:422-424. (Pubitemid 24204755)
42. Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency: a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999;82:1240-1246. (Pubitemid 29473785)
43. Renne T, Oschatz C, Seifert S, et al. Factor XI deficiency in animal models. J Thromb Haemost 2009;7(Suppl 1):79-83.
44. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008;111:4113-4117.
45. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003;1:658-661.
46. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009;7(Suppl 1):84-87. Recent and comprehensive review about clinics and therapy of hereditary FXI defiency in patients.
47. Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011;105:269-273.
48. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(Suppl 2):S5-S12.
49. Campos IT, Amino R, Sampaio CA, et al. Infestin, a thrombin inhibitor present in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. Insect Biochem Mol Biol 2002;32:991-997. (Pubitemid 35025332)
50. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010;121:1510-1517.
51. Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009;206:2381-2395.
52. Robert S, Bertolla C, Masereel B, et al. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem 2008;51:3077-3080. (Pubitemid 351821868)
53. Kraft P, Schwarz T, Pochet L, et al. COU254, a specific 3-carboxamidecoumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke. Exp Transl Stroke Med 2010;2:5.
54. Carter TH, Everson BA, Ratnoff OD. Cabbage seed protease inhibitor: a slow, tight-binding inhibitor of trypsin with activity toward thrombin, activated Stuart factor (factor Xa), activated Hageman factor (factor XIIa), and plasmin. Blood 1990;75:108-115. (Pubitemid 20031497)
55. Hojima Y, Pierce JV, Pisano JJ. Pumpkin seed inhibitor of human factor XIIa (activated Hageman factor) and bovine trypsin. Biochemistry 1982;21:3741-3746. (Pubitemid 13230943)
56. Krishnamoorthi R, Gong YX, Richardson M. A new protein inhibitor of trypsin and activated Hageman factor from pumpkin (Cucurbita maxima) seeds. FEBS Lett 1990;273:163-167. (Pubitemid 20362457)
57. Mahoney WC, Hermodson MA, Jones B, et al. Amino acid sequence and secondary structural analysis of the corn inhibitor of trypsin and activated Hageman Factor. J Biol Chem 1984;259:8412-8416. (Pubitemid 14090598)
58. Campos IT, Tanaka-Azevedo AM, Tanaka AS. Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett 2004;577:512-516. (Pubitemid 39535340)
59. Ulmer JS, Lindquist RN, Dennis MS, Lazarus RA. Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein. FEBS Lett 1995;365:159-163.
60. Schumacher WA, Luettgen JM, Quan ML, Seiffert DA. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010;30:388-392. The comprehensive review gives an overview about coagulation factor XI and its inhibitors and summarizes current strategies to target this protease as an anticoagulant therapy.
61. Takahashi M, Yamashita A, Moriguchi-Goto S, et al. Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res 2010;125:464-470.
62. Yamashita A, Nishihira K, Kitazawa T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006;4:1496-1501.
63. Gruber A, Hanson SR. Factor XI-dependence of surface-and tissue factorinitiated thrombus propagation in primates. Blood 2003;102:953-955. (Pubitemid 36917789)
64. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009;113:936-944.
65. Lin J, Deng H, Jin L, et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem 2006;49:7781-7791. (Pubitemid 46039665)
66. Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007;570:167-174. (Pubitemid 47247686)
67. Buchanan MS, Carroll AR, Wessling D, et al. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa. J Med Chem 2008;51:3583-3587. (Pubitemid 351875013)
68. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116:4684-4692. Zhang et al. described a new approach targeting FXI by RNA interference for prevention of arterial and venous thrombosis without increasing the risk of bleeding. FXI antisense oligonucleotide may be a potential strategy to interfere with thrombosis in humans.
69. Crooke ST. Antisense strategies. Curr Mol Med 2004;4:465-487. (Pubitemid 38961192)
70. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-1735. (Pubitemid 44607121)
71. Mac Leod R, Crosby J, Zhao C. Pharmacological characterization and structure activity relationship of FXI antisense oligonucleotides in cynomolgus monkeys. Blood (ASH Annual Meeting Abstracts) 2009;114.